Initiator Pharma A/S

INIT · Nasdaq Stockholm · Healthcare

2.03SEK +1.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: −40.3%

Performance

1 month

−13.2%

1 year

−40.3%

3 years, per year

−36.0%

5 years, per year

−27.5%

Largest fall, 3 years

−80.8%

Below the peak now

−81.3%

Volatility, 1 year

50.4%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

10.6

Dividend yield

0.0%

Return on equity

−328.3%

Net margin

–

Market value

14 m USD

Quality, value and trend

Where Initiator Pharma stands against every Nordic stock today. 100 is best.

Quality56

Profitability and a sound balance sheet over time. Better than 56% of Nordic stocks.

Value1

The price measured against earnings, assets and cash flow. Better than 1% of Nordic stocks.

Trend8

The price development over the past year. Better than 8% of Nordic stocks.

Combined6

Quality, value and trend together. Better than 6% of Nordic stocks.

About Initiator Pharma

Initiator Pharma A/S is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1 employees.

Initiator Pharma A/S, a clinical-stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous systems. The company is developing Pudafensine, a monoamine reuptake inhibitor that has completed a Phase IIb clinical trial primarily targeting the dopamine system for the treatment of treatment-resistant organic erectile dysfunction; a Phase IIa trial for the treatment of vulvodynia; and preclinical development for the treatment of female sexual dysfunction (FSD).

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis